Cancer in relatives of retinoblastoma patients.

Medical histories with emphasis on malignant disease were obtained on 1,269 first and second degree relatives of 93 probands with retinoblastoma and on 671 first and second degree relatives of 50 age-matched control children. The number of nonocular malignancies expected to occur in first and second degree relatives of the probands were calculated using the observed number of neoplasms in control families as the standard. Using a Poisson distribution to evaluate the findings, a statistically significant excess of cancer was found in relatives of the probands with retinoblastoma.

Flow cytometry of uveal melanomas.

Tumor cell kinetic parameters were determined for 36 uveal melanomas retained in fixed tissue sections using flow cytometric techniques and computerized morphometry. By flow cytometry the majority of cells comprising the 36 tumors were in the G0/G1 phase (55.7%).

Lymphocyte subpopulations before therapy in patients with uveal malignant melanoma.

T-cell and B-cell lymphocyte subpopulations, monocytes, granulocytes, and immunoglobulin receptors were measured with monoclonal antibodies and flow cytometric techniques in the peripheral blood of 266 patients with posterior uveal melanoma before therapy. Statistically significant differences were found in T-helper/inducer (OKT4), T-suppressor/cytotoxic (OKT8), and B-lymphocyte populations between patients with uveal melanoma and age-matched controls.

Metastatic uveal melanoma: an ocular melanoma associated antigen in the serum of patients with metastatic disease.

Two monoclonal antibodies, MAb8-1H and ME491, which bind to different determinants of the same highly glycosylated melanoma-associated antigen, were used to determine melanoma-associated antigen levels in serum samples from patients treated for primary choroidal or ciliary body melanoma and who subsequently developed systemic metastasis. An immunoassay was developed in which ME491 was absorbed to polystyrene beads in order to bind the melanoma-associated antigen present in serum. 125I-MAb8-1H was used to detect the bound antigen.

Antigenic modulation in retinoblastoma: a flow cytometric study.

Flow cytometry (FCM) was used to investigate antigenic expression and modulation during the cell cycle of Y-79 and WERI-Rb1 tissue cultured retinoblastoma cell lines using a polyclonal anti-Y-79 antibody and fluorescein conjugated lectins. Several Y-79 resting cell populations were identified by FCM analysis of antibody binding, while only a single population with uniform antigen expression was found to exist in the synthetic and mitotic phases. WERI-Rb1 cells bound antibody approximately equally in each phase of the cell cycle.